Health Catalyst, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 10, 2025, by Health Catalyst, Inc. (HCAT). The filing primarily announces the entry into a definitive merger agreement to acquire Upfront Healthcare, Inc. ("Upfront"). The report also references a press release issued on January 13, 2025, and a presentation from the J.P. Morgan 2025 Healthcare Conference containing preliminary estimated 2024 results.
Key Financial Metrics and Transaction Details
The filing details the financial structure of the proposed acquisition of Upfront Healthcare, Inc.:
- Closing Consideration: Approximately $86 million, net of cash on hand.
- Consideration Breakdown:
- Cash: Approximately $41.5 million (net of cash on hand).
- Stock: Approximately 5,753,814 shares of Health Catalyst common stock.
- Valuation Basis: Stock consideration valued at a closing reference price of $7.734 per share (35-day average trading price ended January 8, 2025).
- Earn-Out Potential: Up to an additional $33.4 million contingent on performance targets measured as of December 31, 2026.
- Earn-Out Structure: If achieved, 37.5% cash (approx. $12.5 million) and 62.5% stock (approx. 2,699,121 shares).
- Unaccredited Holders: Will receive cash in lieu of stock consideration.
The filing text does not provide specific revenue, profit, cash flow, or margin figures for Health Catalyst or Upfront, other than the transaction values noted above. It references "preliminary estimated 2024 results" in an attached presentation but does not list those specific numbers in the text of this 8-K.
Material Changes and Transaction Timeline
The primary material change is the execution of the Merger Agreement. Key timeline and structural details include:
- Expected Closing: During the quarter ending March 31, 2025.
- Structure: A two-step merger where Upfront becomes a wholly-owned subsidiary of Health Catalyst.
- Termination Rights: The agreement may be terminated if the merger is not consummated by February 25, 2025, or if a Material Adverse Effect occurs.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the deal and the reference to forward-looking statements regarding the 2024 preliminary results and the expected closing timeframe. Significant risks and contingencies identified include:
- Regulatory Approvals: Closing is subject to regulatory approvals, including the expiration of the Hart-Scott Rodino Antitrust Improvements Act waiting period.
- Stockholder Approval: Closing requires requisite approval from Upfront stockholders.
- Performance Targets: The earn-out component is contingent on achieving specific performance targets by December 31, 2026.
- Forward-Looking Uncertainty: Actual results may differ materially due to factors such as failure to obtain regulatory approval, termination of the agreement, or changes in financial performance.
Key Facts for Investor Verification
- Verify the final closing date, as it is currently expected only within the quarter ending March 31, 2025.
- Confirm the specific "preliminary estimated 2024 results" referenced in the J.P. Morgan presentation (Exhibit 99.3) which are not detailed in this text.
- Monitor the status of regulatory approvals and the Hart-Scott Rodino waiting period expiration.
- Review the specific earn-out performance targets for Upfront to assess the likelihood of the additional $33.4 million payout.
- Check for any updates regarding the termination date of February 25, 2025, if the merger has not closed by then.